Of note, while these findings need to be verified in larger, independent RCC cohorts, measuring circulating IL-18BP plasma levels at baseline and on treatment (e.g., after 3 cycles of treatment, as done here) would likely not be difficult to implement into clinical practice if indeed the sensitivity and specificity in larger cohorts remain high. Here, IL18BP is linked to renal cell carcinoma.